Agenda Sessions:
- • Recent Advances in Discovery Technologies
- • Development of Immunotherapies
- • Creative Protein Engineering and Design Approaches
- • Next Generation Bioconjugates
- • Unlocking New Biology with Novel Scaffolds and Antibody Fragments as Therapeutics
- • Addressing Difficult Targets with Protein Therapeutics
- • Delivery of Proteins
- • Emerging Methods and Technologies for Screening, Selection and Sequencing
- • Novel Therapeutic Peptide Development
- • Bispecific and Multispecifics - New Advances and Approaches
- • Bispecific and Multispecifics - Engineering Developability into Multi-Functional Protein Therapeutics
- • Bispecific and Multispecifics - Clinical Case Studies
- • Molecular Imaging
- • Aggregation and Immunogenicity
- • Peter Senter, Ph.D., Vice President, Chemistry, Seattle Genetics
- • Jennifer Cochran, Ph.D., Associate Professor of Bioengineering and Chemical Engineering, Stanford University
- • K. Dane Wittrup, Professor, Chemical Engineering & Biological Engineering, MIT
- • Gary Starling, Ph.D., Associate Vice President, Biologics Discovery Operations, Merck
- • Robert Lutz, Ph.D., Vice President, Translational Research and Development, ImmunoGen, Inc.
- • Robyn Barfield, Ph.D. Group Leader, Bioconjugation, Catalent Pharma Solutions
- • Dimiter Dimitrov, Ph.D., Senior Investigator, Protein Interactions, National Cancer Institute, NIH
- • Arne Skerra, Ph.D., Chief Scientific Officer, XL Protein
- • Dasa Lipovsek, Ph.D., Senior Principal Scientist, Bristol-Myers Squibb
- • David Urech, Ph.D., Co-CEO and Chief Scientific Officer, Numab, Switzerland
- • Joachim Feldwisch, Ph.D., Director Preclinical Development, Affibody Ab, Sweden
- • Catherine Hutchings, Ph.D., Antibody Alliance Management & Strategic Partnering, Heptares Therapeutics Ltd., United Kingdom
- • Andrew Bradbury, Ph.D., Ph.D., Research Scientist and Team Leader, Los Alamos
- • Patrick Baeuerle, Vice President, Research; General Manager, Amgen Research GmbH, Germany
- • Aaron Sato, Ph.D., Vice President of Research, Sutro Biopharma
- • Volker Schellenberger, Ph.D., President and CEO, Amunix
- • Zhenping Zhu, MD, Ph.D., Executive Vice President, Global Biopharmaceuticals, Kadmon Corporation
- • Kaspar Binz, Ph.D., Vice President and Co-Founder, Molecular Partners AG, Switzerland
- • Olivier Laurent, Ph.D., Vice President, CMC, Ambrx
- • Steven Jacobs, Ph.D., Associate Scientific Director, Biologics Research, Janssen R&D
- • Antonin de Fougerolles, Ph.D., Chief Scientific Officer, Ablynx, Belgium
- • Dragan Grabulovski, Ph.D., Chief Scientific Officer, Covagen AG, Switzerland
- • Fredrik Frejd, Ph.D., Chief Scientific Officer, Affibody AB, Sweden
- • Bradley Pentelute, Ph.D., Assistant Professor, MIT
- • Jean E. Lachowicz, Ph.D., Chief Scientific Officer, Angiochem
- • Mark Dennis, Ph.D., Principal Scientist, Antibody Engineering, Genentech, Inc.
- • Gregory C. Ippolito, Ph.D., Research Assistant Professor, Department of Molecular Biosciences, The University of Texas at Austin
Share this article with your social network, just click below to share now!
|
|
No comments :
Post a Comment